Loading...
•
Dec 31, 2021
Black Diamond Therapeutics Q4 2021 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.
Key Takeaways
Black Diamond Therapeutics reported a net loss of $25.9 million for Q4 2021, compared to a net loss of $22.6 million for the same period in 2020. The company's cash, cash equivalents, and investments totaled $209.8 million as of December 31, 2021, which is expected to fund operations into 2024.
Initiated Phase 1 study of BDTX-1535 for GBM and NSCLC after IND allowance by the FDA.
Presented preclinical data at AACR-NCI-EORTC (ANE) International Conference for MasterKey programs BDTX-1535, CNS-BRAF (BDTX-4933), and FGFR.
Appointed Elizabeth Montgomery as Chief People Officer.
Ended 2021 with $209.8 million in cash, cash equivalents, and investments, expected to be sufficient to fund operations into 2024.
Forward Guidance
Black Diamond believes that its cash, cash equivalents and investments of approximately $209.8 million is sufficient to fund its anticipated operating expenses and capital expenditure requirements into 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...